PRODUCT DETAILS

About Bilypsa Tablet

SAROGLITAZAR is an insulin sensitiser used to treat diabetic dyslipidaemia/hypertriglyceridemia in type-2 diabetic patients, which is not controlled by statins (lipid-lowering agents) alone. SAROGLITAZAR has both lipid and glucose-lowering effects in a single molecule; thereby, helping lower blood triglycerides and blood glucose levels. Diabetic dyslipidaemia is characterised by increased triglyceride levels, low-density lipoproteins (LDL), and decreased high-density lipoprotein (HDL) levels. This condition is common in people with type-2 diabetes mellitus.
 
SAROGLITAZAR contains ‘Saroglitazar’, which has dual Peroxisome Proliferator-Activated Receptor (PPAR)-α/γ agonist having a strong PPAR-alpha effect and moderate PPAR-gamma effect. PPAR-alpha reduces the synthesis and secretion of triglycerides and increases lipolysis and hepatic oxidation of fatty acids. It also induces an increase in the synthesis of HDL cholesterol. PPAR-gamma reduces the metabolic burden on the liver, and muscle and promotes glucose utilisation. It improves post-absorptive insulin-mediated suppression of hepatic glucose output. Thereby, SAROGLITAZAR helps in lowering blood triglycerides and blood glucose levels.

Uses of Bilypsa Tablet

Diabetic dyslipidemia/hypertriglyceridemia

Medicinal Benefits of Bilypsa Tablet

SAROGLITAZAR is an insulin sensitiser used to treat diabetic dyslipidaemia/hypertriglyceridemia in type-2 diabetes, which is not controlled by statins alone. SAROGLITAZAR has demonstrated reduction of triglycerides (TG), Low-Density Lipoprotein (LDL) cholesterol, non-High-Density Lipoprotein (non- HDL) cholesterol, Very Low-Density Lipoprotein (VLDL) cholesterol, and an increase in HDL cholesterol. It has also shown glycemic indices by lowering the fasting plasma glucose and glycosylated haemoglobin in diabetic patients. SAROGLITAZAR has dual Peroxisome Proliferator-Activated Receptor (PPAR)-α/γ agonist having strong PPAR-alpha effect and moderate PPAR-gamma effect. PPAR-alpha reduces the synthesis and secretion of triglycerides, increases lipolysis and hepatic oxidation of fatty acids. It also induces an increase in the synthesis of HDL cholesterol. PPAR-gamma reduces the metabolic burden on the liver, muscle and promotes glucose utilisation, and improves post-absorptive insulin-mediated suppression of hepatic glucose output. SAROGLITAZAR has both lipid and glucose-lowering effects in a single molecule; this helps in lowering blood triglycerides and blood glucose levels as well. It also helps in improving insulin resistance. SAROGLITAZAR offers a superior safety profile, greater efficacy on lipid regulation, and excellent glycaemic control.

Directions for Use

Take SAROGLITAZAR with or without food at the same time daily. Swallow SAROGLITAZAR as a whole with a glass of water; do not break or chew the tablet. Based on your medical condition, your doctor will advise for how long you need to take SAROGLITAZAR.

Side Effects of Bilypsa Tablet

• Gastritis (stomach inflammation)
• Nausea
• Vomiting
• Asthenia (weakness)
• Chest discomfort
• Dizziness
• Pyrexia (fever)

Similar Drugs

For informational purposes only. Consult a doctor before taking any medicines.

In-Depth Precautions and Warning

Drug-Drug Interaction:

No interactions were found/established.

Safety Advice

ALCOHOL

You are recommended to avoid alcohol consumption while taking SAROGLITAZAR to prevent unpleasant side effects.

DRIVING

SAROGLITAZAR may cause dizziness. Therefore, drive or operate machinery only if you are alert.

 

LIVER

SAROGLITAZAR should be used with caution in patients with liver disease.

KIDNEY

SAROGLITAZAR should be used with caution in patients with kidney disease.